Search

Your search keyword '"Canale, Filippo A."' showing total 26 results
Start Over Author "Canale, Filippo A."
26 results on '"Canale, Filippo A."'

1. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

2. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation

Author

Martino, Massimo, Gori, Mercedes, Porto, Gaetana, Pellicano, Maria, Santoro, Ludovica, Verduci, Chiara, Canale, Filippo Antonio, Loteta, Barbara, Moscato, Tiziana, Alati, Caterina, Ieracitano, Maria Consuelo, Cuzzocrea, Amelia, Altomonte, Maria, Florenzano, Maria Teresa, Morabito, Antonella, Irrera, Giuseppe, Naso, Virginia, Pugliese, Marta, Console, Giuseppe, Ferreri, Anna, Imbalzano, Lucrezia, Tripepi, Giovanni, and Pitino, Annalisa

Published
2023
Full Text
View/download PDF

4. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Author

Loteta, Barbara, Paviglianiti, Annalisa, Naso, Virginia, Ferreri, Anna, Moscato, Tiziana, Console, Giuseppe, Canale, Filippo Antonio, Irrera, Giuseppe, Pugliese, Marta, Di Costanzo, Antonella, Provenzano, Pasquale Fabio, Loddo, Viviana, Porto, Gaetana, Cusumano, Giuseppa, Russo, Letteria, Meliambro, Nicola, Romeo, Valentina, Porcino, Domenico, Gallo, Salvatore, Gangemi, Tiziana, Rossetti, Antonio Maria, and Martino, Massimo

Published
2022
Full Text
View/download PDF

5. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study

Author

Malagola, Michele, Polverelli, Nicola, Martino, Massimo, Patriarca, Francesca, Bruno, Benedetto, Giaccone, Luisa, Grillo, Giovanni, Bramanti, Stefania, Bernasconi, Paolo, De Gobbi, Marco, Natale, Annalisa, Terruzzi, Elisabetta, Olivieri, Attilio, Chiusolo, Patrizia, Carella, Angelo Michele, Casini, Marco, Maffini, Enrico, Nozzoli, Chiara, Mazza, Patrizio, Bassi, Simona, Onida, Francesco, Vacca, Adriana, Falcioni, Sadia, Luppi, Mario, Iori, Anna Paola, Pavone, Vincenzo, Skert, Cristina, Carluccio, Paola, Borghero, Carlo, Proia, Anna, Selleri, Carmine, Rubini, Vicky, Sacchi, Nicoletta, Oldani, Elena, Bonifazi, Francesca, Ciceri, Fabio, Russo, Domenico, Bernardi, Simona, Farina, Mirko, Fiore, Maria, Lupo Stanghellini, Maria Teresa, Fanin, Renato, Faraci, Danilo Giuseppe, Castagna, Luca, Colombo, Anna Amelia, Nicoli, Paolo, Santarone, Stella, Scortechini, Ilaria, Metafuni, Elisabetta, Merla, Emanuela, Cavattoni, Irene, Cutini, Ilaria, Mazzone, Annamaria, Saporiti, Giorgia, Canale, Filippo Antonio, Piras, Eugenia, Galieni, Piero, Debbia, Giulia, Rocca, Ursula La, Mele, Anna, Carobolante, Francesca, Elice, Francesca, and Fanelli, Fulvia

Published
2023
Full Text
View/download PDF

6. Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study

Author

Martino, Massimo, Pitino, Annalisa, Gori, Mercedes, Viens, Patrice, Siena, Salvatore, Tripepi, Giovanni, Canale, Filippo Antonio, Ballestrero, Alberto, Zamagni, Claudio, Musso, Maurizio, Zambelli, Alberto, Dreger, Peter, Badoglio, Manuela, Secondino, Simona, Console, Giuseppe, Chabannon, Christian, and Pedrazzoli, Paolo

Published
2022
Full Text
View/download PDF

7. Effectiveness of CAR-T treatment toward the potential risk of second malignancies.

Author

Martino, Massimo, Porto, Gaetana, Policastro, Giorgia, Alati, Caterina, Loteta, Barbara, Micó, Maria Caterina, Argiro', Clizia, Altomonte, Maria, Moscato, Tiziana, Labate, Demetrio, Dattola, Vincenzo, Rao, Carmelo Massimiliano, Cogliandro, Francesca, Canale, Filippo Antonio, Naso, Virginia, Filippelli, Gianfranco, Iaria, Antonino, and Pitea, Martina

Subjects
TREATMENT effectiveness, TUMOR lysis syndrome, SKIN cancer, HEMATOPOIETIC stem cell transplantation
Abstract

This document provides a list of references to studies and articles related to CAR-T cell therapy for various types of lymphoma and multiple myeloma. The studies mentioned discuss the outcomes, safety, and efficacy of CAR-T cell therapies such as lisocabtagene maraleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, and idecabtagene vicleucel. The document also includes references to studies that discuss the potential risk of secondary malignancies and other long-term effects associated with CAR-T cell therapy. [Extracted from the article]

Published
2024
Full Text
View/download PDF

9. Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation.

Author

Canale, Filippo Antonio, Pitea, Martina, Alati, Caterina, Porto, Gaetana, Pratico, Giulia, Utano, Giovanna, Germanò, Jessyca, Imbalzano, Lucrezia, Ferreri, Anna, Verduci, Chiara, Santoro, Ludovica, Policastro, Giorgia, Loteta, Barbara, Pugliese, Marta, and Martino, Massimo

Subjects
*EXTRAMEDULLARY diseases, *STEM cell transplantation, *LYMPHOBLASTIC leukemia, *ACUTE leukemia, *CELLULAR therapy, *PLASMACYTOMA
Abstract

Relapsed or refractory (r/r) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) still represent an unmet clinical need despite the new immune therapies available for these patients. We report the case of a Ph + ALL relapsed one year after allogeneic stem cell transplant. After one DLI was started CAR‐T program with brexucabtageneautoleucel, using as bridging treatment ponatinib, vincristine and prednisone. Brexu‐cel infusion was performed in 2023, without CRS or ICANS onset. One month after Brexu‐cel infusion BM aspirate and CT‐PET showed recovery of full donor chimerism, MRD negativity and complete metabolic remission. Subsequently was started maintenance with ponatinib: at last follow‐up, the patient persisted in leukemia‐free status. CAR‐T cells represent the most powerful treatment for r/r Ph + ALL but there is no consensus about the optimal bridging strategy and also regarding the management algorithm during "post CAR‐T phase". Here, we report the efficacy of ponatinib as a bridge to anti‐CD19 CAR‐T cell therapy and as post CAR‐T maintenance. Our experience suggests that a preserving approach with TKI associated to low‐dose chemotherapy can be the optimal bridging therapy prior to CAR‐T and that an "MRD‐guided" and "TKI‐based" maintenance strategy can represent the best choice for Ph + ALL which satisfactorily responds to CAR‐T. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. The Role of MicroRNA in Graft-Versus-Host-Disease: A Review

Author

Pitea, Martina, primary, Canale, Filippo Antonio, additional, Porto, Gaetana, additional, Verduci, Chiara, additional, Utano, Giovanna, additional, Policastro, Giorgia, additional, Alati, Caterina, additional, Santoro, Ludovica, additional, Imbalzano, Lucrezia, additional, and Martino, Massimo, additional

Published
2023
Full Text
View/download PDF

11. Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation

Author

Canale, Filippo Antonio, primary, Pitea, Martina, additional, Alati, Caterina, additional, Porto, Gaetana, additional, Pratico, Giulia, additional, Utano, Giovanna, additional, Germanò, Jessyca, additional, Imbalzano, Lucrezia, additional, Ferreri, Anna, additional, Verduci, Chiara, additional, Santoro, Ludovica, additional, Policastro, Giorgia, additional, Loteta, Barbara, additional, Pugliese, Marta, additional, and Martino, Massimo, additional

Published
2023
Full Text
View/download PDF

13. Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Author

Martino, Massimo, primary, Naso, Virginia, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Pugliese, Marta, additional, Alati, Caterina, additional, Musuraca, Gerardo, additional, Nappi, Davide, additional, Gaimari, Anna, additional, Nicolini, Fabio, additional, Mazza, Massimiliano, additional, Bravaccini, Sara, additional, Derudas, Daniele, additional, Martinelli, Giovanni, additional, and Cerchione, Claudio, additional

Published
2022
Full Text
View/download PDF

14. Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Author

Malagola, Michele, primary, Polverelli, Nicola, additional, Martino, Massimo, additional, Rubini, Vicky, additional, Lupo Stanghellini, Maria Teresa, additional, Patriarca, Francesca, additional, Fanin, Renato, additional, Bruno, Benedetto, additional, Giaccone, Luisa, additional, Faraci, Danilo Giuseppe, additional, Grillo, Giovanni, additional, Bramanti, Stefania, additional, Castagna, Luca, additional, Bernasconi, Paolo, additional, Colombo, Anna Amelia, additional, De Gobbi, Marco, additional, Nicoli, Paolo, additional, Natale, Annalisa, additional, Santarone, Stella, additional, Terruzzi, Elisabetta, additional, Olivieri, Attilio, additional, Scortechini, Ilaria, additional, Chiusolo, Patrizia, additional, Metafuni, Elisabetta, additional, Carella, Angelo Michele, additional, Merla, Emanuela, additional, Casini, Marco, additional, Cavattoni, Irene M, additional, Arpinati, Mario, additional, Nozzoli, Chiara, additional, Cutini, Ilaria, additional, Mazza, Patrizio, additional, Mazzone, Annamaria, additional, Bassi, Simona, additional, Onida, Francesco, additional, Saporiti, Giorgia, additional, Canale, Filippo Antonio, additional, Vacca, Adriana, additional, Piras, Eugenia, additional, Galieni, Piero, additional, Falcioni, Sadia, additional, Luppi, Mario, additional, Debbia, Giulia, additional, Iori, Anna Paola, additional, La Rocca, Ursula, additional, Pavone, Vincenzo, additional, Mele, Anna, additional, Skert, Cristina, additional, Carobolante, Francesca, additional, Carluccio, Paola, additional, Borghero, Carlo, additional, Elice, Francesca, additional, Proia, Anna, additional, Fanelli, Fulvia, additional, Selleri, Carmine, additional, Sacchi, Nicoletta, additional, Mammoliti, Sonia, additional, Oldani, Elena, additional, Ciceri, Fabio, additional, Bonifazi, Francesca, additional, and Russo, Domenico, additional

Published
2021
Full Text
View/download PDF

15. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma

Author

Morabito,Fortunato, Tripepi,Giovanni, Martino,Enrica Antonia, Vigna,Ernesto, Mendicino,Francesco, Morabito,Lucio, Todoerti,Katia, Al-Janazreh,Hamdi, D’Arrigo,Graziella, Canale,Filippo Antonio, Cutrona,Giovanna, Neri,Antonino, Martino,Massimo, and Gentile,Massimo

Subjects
Drug Design, Development and Therapy
Abstract

Fortunato Morabito,1,2 Giovanni Tripepi,3 Enrica Antonia Martino,4 Ernesto Vigna,4 Francesco Mendicino,4 Lucio Morabito,5 Katia Todoerti,6 Hamdi Al-Janazreh,2 Graziella D’Arrigo,3 Filippo Antonio Canale,7 Giovanna Cutrona,8 Antonino Neri,6,8 Massimo Martino,9 Massimo Gentile4 1Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy; 2Hematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel; 3HCNR-IBIM, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, Reggio, Calabria, Italy; 4Hematology Unit, AO of Cosenza, Cosenza, Italy; 5Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy; 6Hematology, Fondazione Cà Granda IRCCS Policlinico, Milan, Italy; 7Stem Cell Transplant Program, Clinical Section, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio, Calabria, Italy; 8IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 9Department of Oncology and Hemato-oncology, University of Milan, Milan, ItalyCorrespondence: Fortunato MorabitoBiotechnology Research Unit, AO of Cosenza, Contrada San Nicola, Cosenza, Italy, Cosenza, 87100, ItalyTel +39-0984-015863Fax +39-0984-681329Email f.morabito53@gmail.comMassimo GentileHematology Unit, AO of Cosenza, Italy, viale della Repubblica snc, Cosenza, 87100, ItalyTel +39-0984-681329Fax +39-0984-681329Email massim.gentile@tiscali.itAbstract: Despite recent therapeutic advances, multiple myeloma (MM) patients experience relapses as they become resistant to various classes and combinations of treatment. Melphalan (L-PAM) is an ageless drug. However, its use in the autologous stem cell transplantation (ASCT) setting and the innovative quadruplet regimen as well as daratumumab, bortezomib, and prednisone make this old drug current yet. Melflufen is a peptide-conjugated alkylator belonging to a novel class of compounds, representing an overcoming of L-PAM in terms of mechanism of action and effectiveness. The improved melflufen cytotoxicity is related to aminopeptidase activity, notably present in normal and neoplastic cells and remarkably heavily overexpressed in MM cells. Upon entering a cell, melflufen is cleaved by aminopeptidases, ultimately releasing the L-PAM payload and eliciting further the inflow and cleavage of the conjugated peptide. This virtuous loop persists until all extracellular melflufen has been utilized. The aminopeptidase-driven accumulation results in a 50-fold increase in L-PAM cell enrichment as compared with free alkylator. This condition produces selective cytotoxicity, increased on-target cell potency, and decreased off-target cell toxicity, ultimately overcoming resistance pathways triggered by previous treatments, including alkylators. Due to its distinct mechanism of action, melflufen plus dexamethasone as a doublet, and in combination with other novel drugs, has the potential to be beneficial for a broad range of patients with relapsed/refractory (RR) MM in third- or even in second-line therapy. The safety profile of melflufen has been consistent across studies, and no new safety concerns have been identified when melflufen was administered in doublet and triplet combinations. Based on growing clinical evidence, melflufen could be not only a good addition in the fight against RRMM but also a drug with a very favorable tolerability profile.Keywords: multiple myeloma, relapsed resistant, melphalan flufenamide, melflufen, therapy, melphalan

Published
2021

16. Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience

Author

Martino, Massimo, primary, Pitino, Annalisa, additional, Gori, Mercedes, additional, Bruno, Benedetto, additional, Crescimanno, Alessandra, additional, Federico, Vincenzo, additional, Picardi, Alessandra, additional, Tringali, Stefania, additional, Ingrosso, Claudia, additional, Carluccio, Paola, additional, Pastore, Domenico, additional, Musuraca, Gerardo, additional, Paviglianiti, Annalisa, additional, Vacca, Adriana, additional, Serio, Bianca, additional, Storti, Gabriella, additional, Mordini, Nicola, additional, Leotta, Salvatore, additional, Cimminiello, Michele, additional, Prezioso, Lucia, additional, Loteta, Barbara, additional, Ferreri, Anna, additional, Colasante, Fabrizia, additional, Merla, Emanuela, additional, Giaccone, Luisa, additional, Busca, Alessandro, additional, Musso, Maurizio, additional, Scalone, Renato, additional, Di Renzo, Nicola, additional, Marotta, Serena, additional, Mazza, Patrizio, additional, Musto, Pellegrino, additional, Attolico, Immacolata, additional, Selleri, Carmine, additional, Canale, Filippo Antonio, additional, Pugliese, Marta, additional, Tripepi, Giovanni, additional, Porto, Gaetana, additional, Martinelli, Giovanni, additional, Carella, Angelo Michele, additional, and Cerchione, Claudio, additional

Published
2021
Full Text
View/download PDF

17. Identifying and Managing CAR T-Cell–Mediated Toxicities: on behalf of an Italian CAR-T Multidisciplinary Team

Author

Martino, Massimo, primary, Macheda, Sebastiano, additional, Aguglia, Umberto, additional, Arcudi, Luciano, additional, Pucci, Giulia, additional, Martino, Bruno, additional, Altomonte, Maria, additional, Rossetti, Antonio Maria, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Imbalzano, Lucrezia, additional, Stelitano, Caterina, additional, Alati, Caterina, additional, Germano’, Jessyca, additional, Labate, Demetrio, additional, Amalfi, Vincenzo, additional, Florenzano, Maria Teresa, additional, Morabito, Antonella, additional, Borzumati, Vittoria, additional, Dattola, Vincenzo, additional, Gattuso, Caterina, additional, Moschella, Antonio, additional, Quattrone, Domenico, additional, Curmaci, Francesco, additional, Franzutti, Claudio, additional, Scappatura, Giuseppe, additional, Rao, Carmelo Massimiliano, additional, Loddo, Viviana, additional, Pontari, Antonella, additional, Pellicano’, Maria, additional, Surace, Rosangela, additional, Sanguedolce, Cristina, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Irrera, Giuseppe, additional, Console, Giuseppe, additional, Moscato, Tiziana, additional, Loteta, Barbara, additional, Canale, Filippo Antonio, additional, Trimarchi, Alfonso, additional, Monteleone, Renza, additional, Said, Al Sayyad, additional, Cirrone, Frank, additional, and Bruno, Benedetto, additional

Published
2021
Full Text
View/download PDF

18. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

Author

Loteta, Barbara, primary, Paviglianiti, Annalisa, additional, Naso, Virginia, additional, Ferreri, Anna, additional, Moscato, Tiziana, additional, Console, Giuseppe, additional, Canale, Filippo Antonio, additional, Irrera, Giuseppe, additional, Pugliese, Marta, additional, Di Costanzo, Antonella, additional, Provenzano, Pasquale Fabio, additional, Loddo, Viviana, additional, Porto, Gaetana, additional, Cusumano, Giuseppa, additional, Russo, Letteria, additional, Meliambro, Nicola, additional, Romeo, Valentina, additional, Porcino, Domenico, additional, Gallo, Salvatore, additional, Gangemi, Tiziana, additional, Rossetti, Antonio Maria, additional, and Martino, Massimo, additional

Published
2021
Full Text
View/download PDF

19. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma

Author

Martino, Massimo, primary, Canale, Filippo Antonio, additional, Alati, Caterina, additional, Vincelli, Iolanda Donatella, additional, Moscato, Tiziana, additional, Porto, Gaetana, additional, Loteta, Barbara, additional, Naso, Virginia, additional, Mazza, Massimiliano, additional, Nicolini, Fabio, additional, Ghelli Luserna di Rorà, Andrea, additional, Simonetti, Giorgia, additional, Ronconi, Sonia, additional, Ceccolini, Michela, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Cerchione, Claudio, additional

Published
2021
Full Text
View/download PDF

21. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team

Author

Martino, Massimo, Macheda, Sebastiano, Aguglia, Umberto, Arcudi, Luciano, Pucci, Giulia, Martino, Bruno, Altomonte, Maria, Rossetti, Antonio Maria, Cusumano, Giuseppa, Russo, Letteria, Imbalzano, Lucrezia, Stelitano, Caterina, Alati, Caterina, Germano’, Jessyca, Labate, Demetrio, Amalfi, Vincenzo, Florenzano, Maria Teresa, Morabito, Antonella, Borzumati, Vittoria, Dattola, Vincenzo, Gattuso, Caterina, Moschella, Antonio, Quattrone, Domenico, Curmaci, Francesco, Franzutti, Claudio, Scappatura, Giuseppe, Rao, Carmelo Massimiliano, Loddo, Viviana, Pontari, Antonella, Pellicano’, Maria, Surace, Rosangela, Sanguedolce, Cristina, Naso, Virginia, Ferreri, Anna, Irrera, Giuseppe, Console, Giuseppe, Moscato, Tiziana, Loteta, Barbara, Canale, Filippo Antonio, Trimarchi, Alfonso, Monteleone, Renza, Al Sayyad, Said, Cirrone, Frank, and Bruno, Benedetto

Abstract

ABSTRACTIntroductionChimeric antigen receptor (CAR)-T-cell therapy is a new treatment for patients with hematologic malignancies in which other therapies have failed.Areas coveredThe review provides an overview for recognizing and managing the most acute toxicities related to CAR-T cells.Expert opinionThe development of immune-mediated toxicities is a common challenge of CAR-T therapy. The mechanism that determines this toxicity is still unclear, although an unfavorable tumor microenvironment and a pro-inflammatory state put patients at risk. The monitoring, diagnosis, and treatment of post-CAR-T toxicities must be determined and based on international guidelines and internal clinical practice. It is urgent to identify biomarkers that can identify patients at greater risk of developing complications. The adoption of consistent grading criteria is necessary to improve toxicity management strategies continually. The first-line therapy consists of supportive care and treatment with tocilizumab or corticosteroids. An early start of cytokine blockade therapies could mitigate toxicity. The plan will include cytokine release prophylaxis, a risk-adapted treatment, prevention of on-target/off-tumor effect, and a switch on/off CAR-T approach.

Published
2022
Full Text
View/download PDF

22. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas

Author

Manconi, Lorenzo, primary, Coviello, Elisa, additional, Canale, Filippo, additional, Giannoni, Livia, additional, Minetto, Paola, additional, Guolo, Fabio, additional, Clavio, Marino, additional, Marcolin, Riccardo, additional, Cea, Michele, additional, Cagnetta, Antonia, additional, Gobbi, Marco, additional, Miglino, Maurizio, additional, Ballerini, Filippo, additional, and Lemoli, Roberto Massimo, additional

Published
2019
Full Text
View/download PDF

24. Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma

Author

Guolo, Fabio, primary, Minetto, Paola, additional, Ballerini, Filippo, additional, Canale, Filippo Antonio, additional, Frello, Michela, additional, Coviello, Elisa, additional, Manconi, Lorenzo, additional, Kunkl, Annalisa, additional, Tedone, Elisabetta, additional, Mangerini, Rosa, additional, Contini, Paola, additional, Fenoglio, Daniela, additional, Miglino, Maurizio, additional, Bo, Alessandra, additional, De Luigi, Maria Carla, additional, Ruzzenenti, Maria Rosaria, additional, Carlier, Paolo, additional, Serio, Alberto, additional, Luchetti, Silvia, additional, Marcenaro, Emanuela, additional, Strada, Paolo, additional, Ravetti, Jean Louis, additional, Gobbi, Marco, additional, and Lemoli, Roberto Massimo, additional

Published
2018
Full Text
View/download PDF

25. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.

Author

Manconi, Lorenzo, Coviello, Elisa, Canale, Filippo, Giannoni, Livia, Minetto, Paola, Guolo, Fabio, Clavio, Marino, Marcolin, Riccardo, Cea, Michele, Cagnetta, Antonia, Gobbi, Marco, Miglino, Maurizio, Ballerini, Filippo, and Lemoli, Roberto Massimo

Subjects
DIFFUSE large B-cell lymphomas, STEM cell treatment, WASTE salvage, HEMATOPOIETIC stem cells, DEXAMETHASONE
Abstract

Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplantation are the current standard of care for relapsed or refractory (R/R) lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOx) in 53 R/R diffuse large B cell lymphomas (DLBCL) treated in our center (median lines 2, range 2-5; median age 59, range 22–79). Hematological toxicity was manageable and no patients experienced renal impairment. After 2 courses the overall response rate was 60% (CR 49%, PR 11%). Median overall survival (OS) was 30.53 months (95% CI 11.5–49.55), 3-year OS 40.5%. Twenty-two eligible patients collected HSC and transplantation was performed in 21/22 patients (95%), after a median of 52 days from last cycle. Our results suggest that in DLBCL R-DHAOx has an excellent stem cell mobilizing capability, response rate comparable to cisplatin-containing regimens and good toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department.

Author

Merlo, Giulia, Cozzani, Emanuele, Canale, Filippo, Miglino, Maurizio, Gambella, Massimiliano, Burlando, Martina, and Parodi, Aurora

Subjects
HEMATOLOGIC malignancies, DERMATOLOGY, HEMATOLOGISTS
Abstract

In recent years, dermatologic manifestations in oncohematologic patients have become more common. The aim of our study was to determine the incidence and heterogeneity of skin manifestations in patients followed at our Hematology Department. This observational monocentrical study was conducted on 60 patients. We divided the observed conditions in exanthematous, purpuric, vesicular-bullous, papulonodular, urticarial, and eczematous manifestations. Moreover, all lesions were classified according to pathogenesis, in (a) specific skin manifestations, caused by neoplastic skin infiltration; (b) immune-mediated manifestations, based on immunological mechanisms; and (c) skin lesions due to immunodeficiency. Altogether, 73 clinical manifestations were reported. Specific manifestations (a) were detected in 15.1% of the cases, mainly with papulonodular appearance. Immune-mediated manifestations (b) were found in 37 cases (50.7%), particularly with eczematous or exanthematous appearance, and leukemia was the malignancy most frequently reported in these patients. Eventually, lesions due to immunosuppression (c) were reported in 34.2% of the cases. They were represented by infections and cutaneous malignancies, and usually manifested with papulonodular lesions. Skin lesions in oncohematologic patients are a common event. A multidisciplinary approach based on the collaboration between the hematologist and the dermatologist is crucial to achieve a proper diagnosis, and correctly manage these manifestations. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results